<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02795897</url>
  </required_header>
  <id_info>
    <org_study_id>AAAQ7026</org_study_id>
    <nct_id>NCT02795897</nct_id>
  </id_info>
  <brief_title>Genomic Translation for ALS Care</brief_title>
  <acronym>GTAC</acronym>
  <official_title>Genomic Translation for Amyotrophic Lateral Sclerosis Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ALS Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look for abnormal genes and gene expression profiles that
      help determine why a person develops amyotrophic lateral sclerosis (ALS) and related motor
      neuron diseases (MND) and why their symptoms present and progress with a particular pattern.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In all patients, ALS/MND is caused by the progressive death of motor neurons. However, every
      patient is affected differently. Some develop symptoms in their 80's while others get sick in
      adolescence. Swallowing/speech are affected first in some patients, but most have weakness in
      their hands or feet at onset. Some individuals show very rapid progression, even as others
      live for decades. Finally, some patients have loss of mainly motor neurons in the brain (as
      in primary lateral sclerosis), while others lose mainly lower motor neurons in the spinal
      cord and brain stem (as in progressive muscular atrophy). Research has uncovered a few
      genetic factors that contribute to the variability of ALS/MND. For example, mutations in the
      superoxide dismutase 1 (SOD1) gene makes onset in the legs more likely and decreases the
      chance of developing dementia. Conversely, having a mutated C9ORF72 gene makes dementia much
      more likely. Uncovering additional factors causing ALS variability is an important research
      priority and is likely to provide clues about how to better diagnose and treat the disease.

      This study is called &quot;Genomic Translation for ALS Care&quot; (GTAC). The investigators will
      analyze the genome and gene expression patterns of people with ALS/MND and carry out research
      on that data, finding insights that the investigators hope will translate into better care
      for ALS/MND patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlations of DNA genotype with ALS phenotypes</measure>
    <time_frame>36 months</time_frame>
    <description>Because subjects are followed over their entire disease course and undergo whole genome sequencing of their DNA, this project will study the distinct features (progression and particular symptoms) of subjects with and without mutations in already known ALS genes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlations of gene expression in blood with ALS phenotypes</measure>
    <time_frame>36 months</time_frame>
    <description>Because subjects are followed over their entire disease course and undergo gene expression profiling on their blood sample, this project will study the distinct features (progression and particular symptoms) of subjects with different types of gene expression profiles.</description>
  </primary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>ALS</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA, RNA and Peripheral blood mononuclear cells (PBMCs)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ALS (meeting El Escorial criteria for definite, probable or possible ALS), or
        primary lateral sclerosis or progressive bulbar/muscular atrophy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Study participants meeting all of the following criteria will be eligible for enrollment in
        GTAC:

          1. Men or women of any race or ethnicity aged 18 or older

          2. Diagnosis of familial or sporadic ALS (definite, probable, or possible according to El
             Escorial Criteria, Appendix 1), or those with primary lateral sclerosis or progressive
             bulbar/muscular atrophy forms of motor neuron disease. All-comers with ALS/MND should
             be enrolled without regard to familial vs sporadic or gene mutation status (i.e.
             participants with known gene mutations should still be enrolled), or phenotype.

          3. Capable of providing informed consent and following study procedures (in the case that
             a subject lacks the ability to provide informed consent, informed consent will be
             sought from the subject's surrogate representative).

          4. Willing to return to clinic site (or another participating center) for follow-up care.

        Exclusion Criteria:

        Study participants meeting any of the following criteria during screening evaluation will
        be excluded from enrolling in GTAC:

          1. Invasive ventilation (i.e. tracheostomy) in place.

          2. Non-invasive ventilation dependent (defined as &gt;22 hours per day)

          3. Pregnancy.

          4. Known Human Immunodeficiency Virus (HIV) , chronic Hepatitis B, or Hepatitis C
             (because cells will be frozen down for future cell line generation).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Harms, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ALS Center Research Coordinator</last_name>
    <phone>212-305-2202</phone>
    <email>alscenter@columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedar Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peggy Allred</last_name>
      <phone>424-315-2694</phone>
      <email>Peggy.allred@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Robert Baloh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univeristy of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blake Swihart</last_name>
      <phone>734-763-8284</phone>
      <email>blakeswi@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Goutman, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Ferment</last_name>
      <phone>612-301-1535</phone>
      <email>ferm0016@umn.edu</email>
    </contact>
    <investigator>
      <last_name>George Manousakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>WU Neuromuscular Clinical Studies Line</last_name>
      <phone>314-362-6159</phone>
      <email>neuroclinicalstudies@neuro.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy Miller, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ALS Center Research Coordinator</last_name>
      <phone>212-305-2202</phone>
      <email>alscenter@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Harms, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State College of Medicine</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Crossen</last_name>
      <phone>717-531-0003</phone>
      <phone_ext>280842</phone_ext>
      <email>jcrossen@hmc.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Zachary Simmons, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Lay</last_name>
      <phone>713-441-3057</phone>
      <email>LFLayJr@HoustonMethodist.org</email>
    </contact>
    <investigator>
      <last_name>Stanley Appel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Janecki</last_name>
      <phone>801-581-3724</phone>
      <email>teresaj@genetics.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Summer Gibson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Strom</last_name>
      <phone>206-685-2028</phone>
      <email>rileys@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Leo Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siddharthan Chandran, MD</last_name>
      <phone>44-0-131-465-9519</phone>
      <email>siddharthan.chandran@ed.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Siddharthan Chandran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2016</study_first_submitted>
  <study_first_submitted_qc>June 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Matthew Harms</investigator_full_name>
    <investigator_title>Assistant Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>genetics</keyword>
  <keyword>genomics</keyword>
  <keyword>amyotrophic lateral sclerosis (ALS)</keyword>
  <keyword>primary lateral sclerosis (PLS)</keyword>
  <keyword>progressive muscular atrophy (PMA)</keyword>
  <keyword>motor neuron disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The investigators intend to share DNA, sequencing data, and phenotypic data broadly. Participants will be consented for sharing of GTAC data and samples with the Northeast ALS Consortium (NEALS) repository, with others carrying out ALS/MND research (including other consortia), for biomedical research in general (including use as controls and use by for-profit companies), and with Biogen Idec. Additionally, GTAC has plans to share coded genomic and clinical data with Database of Genotypes and Phenotypes (dbGaP) and a ALS/MND consortium for genomic discovery (ASLGEN). This includes sharing of genetic and phenotypic data with Biogen Idec, a pharmaceutical company that is partnering with GTAC to fund the sequencing of samples.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

